Dr. Ben Cons has more than 30 years’ experience in pharmaceutical R&D and commercialization in the biotech, pharmaceutical and financing sectors. He is a prominent leader in global healthcare and technology, and has 20 years of experience with the NYSE-listed pharmaceutical services company IQVIA where he was SVP for corporate development and its associated investment fund NovaQuest. Currently, Dr. Cons is a Special Partner at the private equity fund Vitruvian, Chairman of Charnwood Molecular and Chairman of Castor EDC. In addition Dr. Cons is a NED of Talking Medicines, Fluidic Analytics and Board Advisor to Azadyne.

Qualifications.

Dr. Cons has a PhD in molecular pharmacology from Southampton University.

Specialisms.

Dr. Cons' early career included working in respiratory drug development, marketing and business development at Glaxo and diagnostic imaging drug development at Schering.